Argos Therapeutics, Therakos Ink Agreement for Regulatory T Cell Technology

Argos Therapeutics has granted Therakos an exclusive license for the development of novel treatments based on regulatory T cell technology developed by Argos.

Regulatory T cells are a specialized subpopulation of T cells that control immune system responses and prevent immune-mediated diseases.

The cells can treat a variety of immune-mediated diseases, including systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, Crohn’s disease and asthma, Argos said.